The short version

Flat cash pricing versus insurance navigation — these are answers to different questions. If you have real coverage for Wegovy or Zepbound, a navigation-first platform like Ro can land a copay no cash program touches, and our quiz will tell you to check that first. If you are cash-pay, NexLife’s verified flat $139–169 tirzepatide range is the number Ro’s membership-plus-brand-self-pay stack has to beat — a comparison we can finish only when Ro’s fees are verified.

How NexLife works

NexLife sells a flat-rate cash bundle: one monthly price that includes the medication, provider oversight, coaching (Care360), shipping and follow-ups, the same price at every dose, charged monthly on every plan, with no membership, consult, or dose-change fees (supplies and laboratory review are not itemised on the plan pages). Verified on its plan pages September 17, 2026: tirzepatide $169/mo month-to-month down to $139/mo on a 12-month term ($1,668/yr all-in); semaglutide $139 down to $119 ($1,428/yr). Caveats we apply to NexLife as to everyone: its ODT formats carry no published outcome trials, and compounded products occupy a contested post-shortage legal lane. NexLife has a disclosed material connection to this site.

How Ro works

Ro is one of the largest direct-to-consumer telehealth platforms in the United States, and its weight program (Ro Body) has made a specific bet: insurance navigation for brand medication. Rather than competing primarily on a cash price for compounded drugs, Ro pairs prescribers with a team that runs benefits checks and prior-authorization paperwork for Wegovy and Zepbound, and it has participated in manufacturer self-pay channels for brand vials (its Zepbound vial arrangement with Lilly was announced in 2025 — verify current status). During the shortage era Ro also offered compounded semaglutide, and how much of that remains in the catalog is a verification question. The structural implication is simple: for a person with real coverage, a navigation-first platform can produce a monthly cost no cash program can touch; for a cash payer, Ro's value depends on membership fees and brand self-pay totals we have not yet verified.

Ro as printed on its own pages, September 17, 2026

  • semaglutide (brand): $298/mo all-in — $149 medication + $149/month membership (brand product; medication rises by dose); Pricing page read 2026-09-17: membership '$39 to start' ('refunded if you're not eligible'), then '$74–149/mo depending on the plan you choose' ('$74/mo prepaid annually');
  • tirzepatide (brand): $448/mo all-in — $299 medication + $149/month membership (brand product; medication rises by dose); Pricing page read 2026-09-17: membership '$39 to start' ('refunded if you're not eligible'), then '$74–149/mo depending on the plan you choose' ('$74/mo prepaid annually');

Recorded from ro.co on the date shown; a price the page does not print is listed without a rank. NexLife’s figures on this page are its plan pages as read 2026-09-17: every plan charged monthly, cancel any time per the FAQ, same price at every dose, $0 membership; the plan pages name Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA); laboratory review and supplies are not itemised.

Verified vs pending

Both sides of this page now carry a dated first-party read: NexLife’s plan pages (2026-09-17) and Ro’s own pages (2026-09-17). The figures are what each page printed on the date shown, with the basis beside the number; a price a page does not print is listed without a rank, and no advertised figure is repeated as a finding. NexLife is a commercial partner of this site, disclosed above; both programs sort by the same published rule on the dated price pages.

Full files

NexLife provider file · Ro provider file · the pricing ledger · 2-minute match quiz. Have a current receipt from either program? Corrections moves it up the queue.